COMP <GO>
RARE vs GPCR // ENTERPRISE SCALE & MARKET CAP
Ultragenyx Pharmaceutical Inc. (NASDAQ) VS. Structure Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: RARE 3
— GPCR 1
▲ ENTERPRISE SCALE & MARKET CAP LEADER: RARE
LAST: $16.30 (+1.24%) • MKT CAP: $1.59B
market-cap
$1.59B
LAST: $20.47 (-6.40%) • MKT CAP: $1.56B
market-cap
$1.56B
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (RARE VS. GPCR)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | RARE | GPCR | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | -19.50% | -15.50 | GPCR | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | -14.43% | — | TIE | /fcf-yield <GO> |
| Operating Margin | -60.00% | — | — | TIE | /operating-margins <GO> |
| Net Profit Margin | -60.00% | — | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 20.20% | — | — | TIE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | — | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 3/9 | 1/9 | +2.00 | RARE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 49.5 | 26.9 | +22.60 | RARE | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap ACTIVE | $1.59B | $1.56B | $27.7M | RARE | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | RARE REV | GPCR REV | RARE GROSS % | GPCR GROSS % | RARE FCF | GPCR FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $673.0M | $494.4M | — | — | -$472.0M | -$225.8M |
| FY 2024 | $560.0M | $443.0M | — | — | -$421.0M | -$117.9M |
| FY 2023 | $434.0M | $287.8M | — | — | -$475.0M | -$79.5M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
RARE // BETA —
GPCR // BETA —